In contrast, the use of compounds that selectively inhibit ERK functions involved in cell survival may have the potential to sensitize cancer cells to other chemotherapeutic agents without inducing the compensatory pathways that lead to acquired drug resistance. The gene discussed is MAPK1; the disease is cancer.